Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-26489112 in photosensitive epilepsy using photoparoxysmal EEG response
2007-004254-93Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of JNJ-26489112 in epilepsy and photosensitive epilepsy (PSE), sponsored by Janssen Pharmaceutical. Primary endpoint: Antiepileptic activity based on photoparoxysmal EEG response. Started Sep 2007; status: completed.
02
Drugs
JNJ-26489112
03
Conditions
epilepsyphotosensitive epilepsy (PSE)
Beyond the preview
Go deeper on 2007-004254-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004254-93.